Ranitidine hydrochloride - Generic Drug Details

What are the generic sources for ranitidine hydrochloride and what is the scope of freedom to operate?

Ranitidine hydrochloride is the generic ingredient in seven branded drugs marketed by Ajanta Pharma Ltd, Appco, Aurobindo Pharma, Dr Reddys Labs Ltd, Novitium Pharma, Rising, Sandoz, Teva, Glaxosmithkline, Glaxo Grp Ltd, Bedford, Hikma, Mylan Labs Ltd, Zydus Pharms Usa Inc, Pai Holdings Pharm, Actavis Mid Atlantic, Amneal Pharms, Apotex Inc, Epic Pharma Llc, Lannett Co Inc, Nostrum Labs Inc, Pharm Assoc, Ranbaxy, Sun Pharma Canada, Tolmar, Torrent, Wockhardt, Chattem Sanofi, Amneal Pharms Ny, Ani Pharms, Apotex, Boehringer Ingelheim, Contract Pharmacal, Dr Reddys Labs Inc, Glenmark Pharms, Granules, Heritage Pharma Avet, Mpp Pharma, Mylan, Perrigo, Perrigo R And D, Ph Health, Pharmobedient, Strides Pharma, Sun Pharm Inds Ltd, Thinq Pharm-cro Pvt, Vkt Pharma, Watson Labs, and Wockhardt Ltd, and is included in eighty-four NDAs. Additional information is available in the individual branded drug profile pages.

There are thirty-two drug master file entries for ranitidine hydrochloride. Seven suppliers are listed for this compound.

Summary for ranitidine hydrochloride

US Patents:	0
Tradenames:	7
Applicants:	49
NDAs:	84
Drug Master File Entries:	32
Finished Product Suppliers / Packagers:	7
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	144
Patent Applications:	6
What excipients (inactive ingredients) are in ranitidine hydrochloride?	ranitidine hydrochloride excipients list
DailyMed Link:	ranitidine hydrochloride at DailyMed

Recent Clinical Trials for ranitidine hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Cairo University	NA
Beijing Wehand-Bio Pharmaceutical Co., Ltd	PHASE1
Cancer Institute and Hospital, Chinese Academy of Medical Sciences	PHASE1

See all ranitidine hydrochloride clinical trials

Pharmacology for ranitidine hydrochloride

Drug Class	Histamine-2 Receptor Antagonist
Mechanism of Action	Histamine H2 Receptor Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for ranitidine hydrochloride

A02BA	H2-receptor antagonists
A02B	DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
A02	DRUGS FOR ACID RELATED DISORDERS
A	Alimentary tract and metabolism

US Patents and Regulatory Information for ranitidine hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxo Grp Ltd	ZANTAC	ranitidine hydrochloride	SYRUP;ORAL	019675-001	Dec 30, 1988		DISCN	Yes	No
Dr Reddys Labs Inc	RANITIDINE HYDROCHLORIDE	ranitidine hydrochloride	TABLET;ORAL	076705-001	Jul 27, 2005	AB	RX	No	No
Rising	RANITIDINE HYDROCHLORIDE	ranitidine hydrochloride	CAPSULE;ORAL	075564-002	Oct 27, 2000		DISCN	No	No
Sun Pharm Inds Ltd	RANITIDINE HYDROCHLORIDE	ranitidine hydrochloride	TABLET;ORAL	075132-001	Jan 14, 2000		DISCN	No	No

Expired US Patents for ranitidine hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pai Holdings Pharm	ZANTAC IN PLASTIC CONTAINER	ranitidine hydrochloride	INJECTABLE;INJECTION	019593-001	Dec 17, 1986
Glaxo Grp Ltd	ZANTAC 150	ranitidine hydrochloride	GRANULE, EFFERVESCENT;ORAL	020251-002	Mar 31, 1994
Glaxosmithkline	ZANTAC 150	ranitidine hydrochloride	CAPSULE;ORAL	020095-001	Mar 8, 1994
Chattem Sanofi	ZANTAC 150	ranitidine hydrochloride	TABLET;ORAL	021698-002	Mar 13, 2007

Ranitidine Hydrochloride: Market Dynamics and Financial Trajectory

Last updated: April 24, 2026

Ranitidine hydrochloride is a legacy histamine-2 (H2) receptor antagonist that peaked as a high-volume, low-cost oral therapy, then collapsed after regulatory action tied to NDMA contamination concerns. The drug moved from global blockbuster status to near-off-market status in major jurisdictions, with financial outcomes dominated by (1) product withdrawals and label restrictions, (2) erosion from generics before the NDMA shock, and (3) a shift in prescriber and payer preference toward proton pump inhibitors (PPIs) and other H2 options with different impurity profiles.

What drove ranitidine’s market rise and mainstream adoption?

H2 positioning and outpatient scale

Ranitidine established itself as a core option for:

• Gastroesophageal reflux disease (GERD)
• Dyspepsia and heartburn
• Peptic ulcer disease support regimens

Its commercial profile reflected the standard H2 playbook: broad indication coverage within acid suppression, oral dosing convenience, and a long cycle of generic competition that kept prices low while sustaining volume.

Price compression from generics

By the time NDMA concerns became actionable in regulators’ frameworks, ranitidine already faced mature generic dynamics in the U.S., EU, and many Asia-Pacific markets. The market structure was characterized by:

• Multiple generic entrants
• Retail pharmacy price competition
• Periodic supply shifts tied to manufacturing compliance and labeling

The result was a “high volume, thin margin” economics model. That profile matters because it made downstream earnings highly sensitive to distribution disruptions and inventory write-offs once recalls began.

How did the NDMA contamination issue reshape the commercial landscape?

The NDMA risk became the defining market event. Regulators and industry actions compressed demand and sales rapidly by restricting access and driving withdrawals.

United States: FDA actions and end-state

• April 1, 2020: FDA requested drug manufacturers withdraw all ranitidine products from the market in the U.S. (press line at the time: “FDA requests drug companies to remove all ranitidine products… from the market.”)
• The withdrawal eliminated mainstream supply for new commercial demand.

United Kingdom: MHRA position

• September 26, 2019: UK regulator (MHRA) advised patients to stop taking ranitidine products and to consult healthcare professionals for alternative treatment while investigation proceeded (MHRA communications at the time).

European Union: national withdrawals and policy alignment

Across EU member states, ranitidine availability narrowed due to pharmacovigilance and impurity investigations, resulting in product withdrawals and switching to alternatives.

Industry response: consumer channel shock

Once withdrawn:

• Prescription demand shifted to PPIs and other H2 blockers
• Remaining inventory faced forced channel discontinuation
• Pharmacies and wholesalers recorded write-downs and returned goods
• Manufacturers redirected supply chains and compliance programs toward alternatives

This combination turned ranitidine from a steady-throughput commodity into a time-bound wind-down product.

Where did market demand go after ranitidine left mainstream supply?

Prescriber switch: toward PPIs and other H2 agents

The substitution pattern was predictable given acid-suppression class norms:

• PPIs captured the largest share of “GERD and chronic acid suppression” demand
• Other H2 receptor antagonists retained some share where prescribers favored H2 economics or patient-specific tolerability

Payer and formulary tightening

Payers tightened formularies after withdrawals and did not reinstate ranitidine in most plans where alternatives were available and policy risk was elevated.

Patient behavior: “stay off the withdrawn product”

Even where alternative H2 therapies were available, the discontinuation event reduced patient willingness to return to ranitidine, particularly because prescribing and counseling shifted away from it during the withdrawal period.

How did financial performance typically evolve from peak volume to collapse?

Ranitidine’s financial trajectory is best described in three phases.

Phase 1: Generic maturity and stable volume economics

• Multiple generic producers stabilized market share through low pricing.
• Earnings at the company and distribution levels tracked volume with limited pricing power.
• Manufacturing and compliance costs became dominant cost drivers as the product aged.

Phase 2: The NDMA shock and rapid sales contraction

• Market disruption followed regulator requests and product withdrawals in 2019-2020.
• Sales declined sharply as supply was removed and prescriptions ended.
• Companies faced:
  • inventory returns and write-downs
  • expedited supply transition for customers
  • legal and compliance costs tied to impurity concerns

Phase 3: Wind-down and replacement-driven stabilization in alternatives

• Ranitidine became a legacy drug with limited remaining availability in some markets until fully withdrawn or discontinued.
• Growth moved to replacement therapies (especially PPIs) rather than to ranitidine.
• Ranitidine’s financial contribution shifted from core revenue to either residual export channels or discontinued product lines.

What does the U.S. regulatory timeline imply for revenue timing?

The U.S. withdrawal timing compresses the revenue ramp-down window to roughly one year at most, with the largest disruption occurring around 2020.

• Sept 26, 2019: UK patient stop advice begins the early demand shock in major English-speaking markets (MHRA).
• Apr 1, 2020: U.S. FDA requests removal of all ranitidine products (FDA).
• 2020 onward: supply and demand effectively end in the U.S. retail and prescription channels.

For financial modeling, ranitidine revenue exposure is therefore front-loaded into the 2019-2020 period, with limited forward recovery.

Market dynamics vs. company financials: what mattered most to earnings?

1) Supply removal and channel returns

Once regulators requested removal, the primary financial drivers were:

• inventory return rates
• chargebacks and customer reimbursement
• reverse logistics costs
• settlement impacts with wholesalers and distributors

2) Pricing power was structurally low

Generic saturation limited the ability to absorb incremental compliance or risk costs via pricing.

3) Replacement demand pulled sales elsewhere

Competitor capture, mainly PPIs, reduced the rebound probability after any temporary supply normalization.

4) Reputational and regulatory compliance overhead

Even after withdrawal, companies incurred ongoing costs for impurity investigations and compliance programs, with no meaningful path to regain the prior demand base.

How does ranitidine’s commercial arc compare to typical legacy H2 products?

Compared with other H2 blockers that did not face equivalent NDMA-driven global withdrawal, ranitidine’s decline is atypical in speed and magnitude.

Typical mature H2 pattern

• Gradual erosion from generics and preference shifts to PPIs
• Slow decline based on formulary and age of molecule

Ranitidine pattern

• Sharp regulatory-driven discontinuation with near-immediate sales cessation after 2020 U.S. actions
• Permanent or near-permanent exclusion from mainstream prescribing

The difference is regulatory takedown rather than competitive substitution alone.

What commercialization risks would an investor or R&D sponsor infer from ranitidine’s case?

For pipeline and in-licensing diligence, ranitidine highlights a category risk: impurity formation and stability can define commercial fate even when the core mechanism remains unchanged.

Key risk dimensions:

• manufacturing controls that affect impurity profiles over time and across sites
• storage and temperature effects that influence NDMA formation
• analytical detection thresholds and regulatory action triggers
• market access fragility once a regulator flags impurity concerns

The financial trajectory after NDMA was not driven by efficacy failure; it was driven by impurity risk governance and regulator decisions.

Current market position: is ranitidine still a significant commercial product?

In major regulated markets, ranitidine is no longer a mainstream product. Its commercial footprint is dominated by:

• discontinued or withdrawn status
• limited residual availability in niche channels depending on jurisdiction and recall completion
• replacement by PPIs and other H2 therapies

The core implication for financial trajectory is that future revenue should be modeled as legacy wind-down rather than growth.

Key Takeaways

• Ranitidine’s market dynamics shifted from generic-driven, high-volume stability to abrupt demand destruction after NDMA contamination concerns.
• The U.S. FDA withdrawal request dated April 1, 2020 is the key financial inflection point for mainstream U.S. revenue.
• Growth did not revert; substitution flowed primarily to PPIs and, to a lesser extent, other H2 antagonists.
• Financial outcomes were dominated by supply removal, channel returns, inventory write-downs, and replacement capture by competing acid-suppression therapies.

FAQs

1. What event caused the largest ranitidine revenue disruption?
   The FDA request on April 1, 2020 for removal of all ranitidine products from the U.S. market tied to NDMA contamination concerns.

2. Did ranitidine fail on efficacy?
   No. The commercial collapse followed impurity risk and regulatory action, not loss of clinical effectiveness.

3. Where did ranitidine demand go after withdrawals?
   Demand shifted mostly to PPIs for GERD and chronic acid suppression, with some substitution to other H2 antagonists where applicable.

4. How fast did the U.S. market shut down after the FDA action?
   The withdrawal request in April 2020 effectively ended mainstream U.S. retail and prescription availability in the short term, limiting any meaningful forward revenue recovery.

5. Is ranitidine still commercially significant in major markets?
   No. In major regulated jurisdictions it is not a mainstream product due to discontinuation/withdrawal, replaced by other acid-suppression options.

---

References (APA)

[1] U.S. Food and Drug Administration. (2020, April 1). FDA requests drug companies to remove all ranitidine products (Zantac) from the market. https://www.fda.gov/news-events/press-announcements/fda-requests-drug-companies-remove-all-ranitidine-products-zantac-market
[2] Medicines and Healthcare products Regulatory Agency. (2019, September 26). Ranitidine: advice to patients. https://www.gov.uk/government/news/ranitidine-advice-to-patients